France’s New President Will Support A Pharma Industry That Produces Innovation At Fair Prices
Executive Summary
Emmanuel Macron, who will be sworn in as the new French president on May 14, is likely to promulgate pro-industry policies, although he has warned that innovation in medicines must come at a “fair price.”
You may also be interested in...
French Pharma Industry Lays Out Wishlist For New Government, Proposes Five-Year Pact
The French pharmaceutical industry association is cautiously optimistic that the new government will take a longer-term view of the industry’s contribution to healthcare, and has proposed a pact setting out the relations between the industry and the state.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.
EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’
Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.